To the best of our knowledge, this is the first study to successfully apply Olaparib monotherapy or in combination with Furmonertinib and intrathecal chemotherapy for NSCLC patients with EGFR and somatic BRCA2 co-mutation following resistance to third-generation EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.